Boston Scientific Corporation (NYSE:BSX) Stock Has Average Target Price of $70.19 According to Brokerages

Boston Scientific Corporation (NYSE:BSX) has received an average recommendation of “Moderate Buy” from the thirty brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $67.96.

Several research firms recently weighed in on BSX. Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Evercore set a $65.00 price target on Boston Scientific in a report on Monday, July 6th. Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Sanford C. Bernstein restated an “outperform” rating and set a $54.00 price objective on shares of Boston Scientific in a research note on Saturday. Finally, Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th.

Boston Scientific Stock Up 0.0%

BSX opened at $42.61 on Wednesday. The firm has a 50 day moving average price of $46.95 and a 200 day moving average price of $51.51. The company has a market cap of $61.75 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.02 and a beta of 0.58. Boston Scientific has a 1 year low of $41.94 and a 1 year high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts expect that Boston Scientific will post 3.25 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in the company. QRG Capital Management Inc. lifted its holdings in Boston Scientific by 129.4% in the 2nd quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after buying an additional 211,855 shares in the last quarter. Andra AP fonden grew its stake in shares of Boston Scientific by 13.9% during the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock valued at $8,264,000 after acquiring an additional 23,694 shares in the last quarter. SkyView Investment Advisors LLC acquired a new stake in shares of Boston Scientific during the second quarter valued at about $107,000. Bullseye Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $41,000. Finally, Rench Wealth Management Inc. increased its position in shares of Boston Scientific by 27.5% during the second quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock worth $1,193,000 after acquiring an additional 6,033 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.